MARKET

DNLI

DNLI

Denali Therapeut
NASDAQ
16.81
-0.21
-1.23%
After Hours: 16.81 0 0.00% 16:10 12/17 EST
OPEN
16.96
PREV CLOSE
17.02
HIGH
17.30
LOW
16.66
VOLUME
1.25M
TURNOVER
--
52 WEEK HIGH
24.35
52 WEEK LOW
10.57
MARKET CAP
2.62B
P/E (TTM)
-5.7746
1D
5D
1M
3M
1Y
5Y
1D
50 heavily shorted laggards poised to rebound according to Wells Fargo
Seeking Alpha · 1d ago
Does Denali Therapeutics' (DNLI) Discounted Equity Raise Reveal a New Phase in Its Risk Strategy?
Simply Wall St · 1d ago
Weekly Report: what happened at DNLI last week (1208-1212)?
Weekly Report · 2d ago
Assessing Denali Therapeutics (DNLI) Valuation After Its $200 Million Follow-On Equity Offering
Simply Wall St · 2d ago
Eli Lilly: The Right Long-Term Strategy
Seeking Alpha · 4d ago
Denali Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 6d ago
Denali Therapeutics Price Target Cut to $30.00/Share From $31.00 by Wedbush
Dow Jones · 6d ago
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
Benzinga · 6d ago
More
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Webull offers Denali Therapeutics Inc stock information, including NASDAQ: DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNLI stock methods without spending real money on the virtual paper trading platform.